<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Nabi Biopharmaceuticals</title>
	<atom:link href="http://www.stockbloghub.com/tag/nabi-biopharmaceuticals/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ALL) Company News for July 19, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/07/19/all-company-news-for-july-19-2011-corporate-summary/79350</link>
		<comments>http://www.stockbloghub.com/2011/07/19/all-company-news-for-july-19-2011-corporate-summary/79350#comments</comments>
		<pubDate>Tue, 19 Jul 2011 18:42:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Property & Casualty Insurance]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Check Point Software Technologies Limited]]></category>
		<category><![CDATA[CHKP]]></category>
		<category><![CDATA[ENTR]]></category>
		<category><![CDATA[Entropic Communications Inc.]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Linkedin Corporation]]></category>
		<category><![CDATA[LNKD]]></category>
		<category><![CDATA[MGIC Investment Corporation]]></category>
		<category><![CDATA[MTG]]></category>
		<category><![CDATA[NABI]]></category>
		<category><![CDATA[Nabi Biopharmaceuticals]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[US Gold Corporation]]></category>
		<category><![CDATA[UXG]]></category>
		<category><![CDATA[Valence Technology Inc]]></category>
		<category><![CDATA[VLNC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79350</guid>
		<description><![CDATA[•    Shares of biotech company Bacterin International Holdings Inc (AMEX:BONE) gained 10.34% after the company posted initial second quarter earnings figures that came in above expectations•    U.S. listed shares of Check Point Software Technologies Ltd. (NASDAQ:CHKP) rose 8.11% after the network security provider released 2011 earnings forecasts exceeding the Street&#8217;s expectations •    According to a report in The Wall Street Journal, contract drug developer Pharmaceutical Product Development, Inc. (NASDAQ:PPDI) is looking to sell itself •    Share prices of U.S. Gold Corporation (NYSE:UXG) gained 5.25% to close at $7.02 after gold futures moved above the $1,600 per ounce mark on the New York Mercantile Exchange •    Bloomberg reported that Bank of America (NYSE:BAC) may further delay its plans to increase dividends because of mounting mortgage losses •    Battery manufacturer Valence Technology, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/19/all-company-news-for-july-19-2011-corporate-summary/79350/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NABI) Nabi Biopharmaceuticals&#8217; Vaccine Program Advances</title>
		<link>http://www.stockbloghub.com/2010/03/19/nabi-nabi-biopharmaceuticals-vaccine-program-advances/31365</link>
		<comments>http://www.stockbloghub.com/2010/03/19/nabi-nabi-biopharmaceuticals-vaccine-program-advances/31365#comments</comments>
		<pubDate>Fri, 19 Mar 2010 22:56:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[NABI]]></category>
		<category><![CDATA[Nabi Biopharmaceuticals]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31365</guid>
		<description><![CDATA[Nabi Biopharmaceuticals (NABI) has initiated the second phase III clinical trial for NicVAX, an investigational vaccine being developed for the treatment of nicotine addiction and preventing smoking relapse. Results from the first phase III trial are expected at the end of 2010. An agreement with the US Food and Drug Administration (FDA) has been reached on the study design, protocol and end points for the trial. Nabi has also received confirmation from the European Medicines Agency (EMEA) supporting the trial protocol. The double blind placebo controlled study would be conducted on 1,000 patients with results expected by early 2012. In November 2009, Nabi and GlaxoSmithKline (GSK) signed a licensing agreement for NicVAX and development of a second generation nicotine vaccine.  The agreement involved a $40 million upfront payment with the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/19/nabi-nabi-biopharmaceuticals-vaccine-program-advances/31365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NABI) Nabi Biopharmaceuticals&#8217; Earnings Reports Bests Estimates</title>
		<link>http://www.stockbloghub.com/2010/03/12/nabi-nabi-biopharmaceuticals-earnings-reports-bests-estimates/30468</link>
		<comments>http://www.stockbloghub.com/2010/03/12/nabi-nabi-biopharmaceuticals-earnings-reports-bests-estimates/30468#comments</comments>
		<pubDate>Fri, 12 Mar 2010 18:46:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[NABI]]></category>
		<category><![CDATA[Nabi Biopharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30468</guid>
		<description><![CDATA[Nabi Biopharmaceuticals (NABI) reported fourth quarter fiscal 2009 (ended Dec 26, 2009) earnings of 2 cents per share (from continuing operations). This was well above the Zacks Consensus Estimate of a loss of 11 cents. The company suffered a loss of 10 cents (from continuing operations) in the year-ago quarter (ended Dec 27, 2008). Nabi&#8217;s loss of 37 cents (from continuing operations) for full year 2009 was against a loss of 44 cents (from continuing operations) in 2008. The Zacks Consensus Estimate for 2009 was a loss of 50 cents. Revenues for the reported quarter came in at $10.5 million which represents the payments recognized from the sale of its PentaStaph drug to GlaxoSmithKline Biologicals S.A., a subsidiary of GlaxoSmithKline plc. (GSK). The amount is inclusive of $3.1 million from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/12/nabi-nabi-biopharmaceuticals-earnings-reports-bests-estimates/30468/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) Anti-Smoking Vaccine Offered by GlaxoSmithKline</title>
		<link>http://www.stockbloghub.com/2009/11/17/gsk-anti-smoking-vaccine-offered-by-glaxosmithkline/20789</link>
		<comments>http://www.stockbloghub.com/2009/11/17/gsk-anti-smoking-vaccine-offered-by-glaxosmithkline/20789#comments</comments>
		<pubDate>Tue, 17 Nov 2009 22:22:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[NABI]]></category>
		<category><![CDATA[Nabi Biopharmaceuticals]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20789</guid>
		<description><![CDATA[GlaxoSmithKline (GSK) and Nabi Biopharmaceuticals (NABI) signed a licensing agreement for a nicotine conjugate vaccine (NicVAX) as well as for the development of a second generation nicotine vaccine. NicVAX is an investigational vaccine for the treatment of nicotine addiction and the prevention of smoking relapse. Earlier in October, the vaccine received a $10 million grant from the National Institute on Drug Abuse. As per the agreement, Nabi will get an upfront payment of $40 million and is eligible to receive more than $500 million (together with upfront payment) as option fees and milestones for the vaccine, NicVAX, and follow-on nicotine vaccines. Nabi has the potential to receive double-digit royalties from sales if the product is commercialized. GlaxoSmithKline will have an option to exclusively in-license NicVAX on a worldwide basis and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/17/gsk-anti-smoking-vaccine-offered-by-glaxosmithkline/20789/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) Glaxo Expands Vaccine Portfolio &#8211; will buy Nabi’s PentaStaph vaccine</title>
		<link>http://www.stockbloghub.com/2009/08/10/gsk-glaxo-expands-vaccine-portfolio-will-buy-nabi%e2%80%99s-pentastaph-vaccine/12263</link>
		<comments>http://www.stockbloghub.com/2009/08/10/gsk-glaxo-expands-vaccine-portfolio-will-buy-nabi%e2%80%99s-pentastaph-vaccine/12263#comments</comments>
		<pubDate>Tue, 11 Aug 2009 02:16:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NABI]]></category>
		<category><![CDATA[Nabi Biopharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12263</guid>
		<description><![CDATA[GlaxoSmithKline (GSK) recently entered an agreement with Nabi Biopharmaceuticals (NABI) to bring a new pipeline candidate into its vaccine portfolio. Glaxo will buy Nabi’s PentaStaph vaccine, which is being developed to fight hospital-acquired staph infection. Staph infections are caused by a drug-resistant strain of bacteria often found in hospitals. PentaStaph is being tested against three different strains of staph and two other antigens. The deal is valued at $46 million, of which $20 million will be paid immediately. The remaining $26 million will be paid after achievement of four key milestones. The deal is scheduled to close by year-end and Nabi expects to achieve the four milestone payments within 18 months. GlaxoSmithKline has a strong presence in the vaccine market. The company’s acquisition of ID Biomedical in 2005 helped Glaxo ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/10/gsk-glaxo-expands-vaccine-portfolio-will-buy-nabi%e2%80%99s-pentastaph-vaccine/12263/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

